Cipla gets CDSCO panel green signal to conduct Paxlovid trials in India
In a significant development, drug-major Cipla has got a green signal from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct local trials on the anti-Covid-19 pill Paxlovid.The SEC of the Central Drugs Standard Control Organization has granted Cipla permission to perform bioavailability and bioequivalence (BA/BE) trials for the...
In a significant development, drug-major Cipla has got a green signal from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct local trials on the anti-Covid-19 pill Paxlovid.
The SEC of the Central Drugs Standard Control Organization has granted Cipla permission to perform bioavailability and bioequivalence (BA/BE) trials for the anti-Covid-19 pill Paxlovid, as per the report published by ET.
For more information, check out the full story on the link below:
Cipla gets CDSCO panel nod to conduct Indian trials of Paxlovid
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd